{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T19:03:27Z","timestamp":1779217407360,"version":"3.51.4"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Alectinib has been approved as first-line treatment for anaplastic lymphoma kinase (ALK)-positive non-small cell lung carcinoma. Oncologists are also exploring the possibility of applying alectinib in the perioperative period. Here, we present a patient with locally advanced lung adenocarcinoma associated with <jats:italic>EML4<\/jats:italic>-<jats:italic>ALK<\/jats:italic> fusion mutation, who received neoadjuvant chemotherapy and alectinib treatment, and then underwent thoracoscopic left lower lung lobectomy. The patient initially received eight chemotherapy cycles and achieved partial remission. After eight cycles of chemotherapy, the lymph nodes in the hilar region again enlarged. The patient was then switched to 4\u00a0months of alectinib therapy, but no significant lesion changes were detected on imaging during this period. This raised the question of whether the patient developed alectinib resistance. The pathological findings of the postoperative lung lobe specimens indicated extensive necrosis in the tumor area with no residual tumor cells and massive chronic inflammatory cell infiltration around the tumor area, confirming inconsistency between the imaging findings and pathological results. Multi-point tumor specimen sampling was postoperatively performed. Tumor immune-related gene expression was detected in the sample with the help of the PanCancer IO360\u2122 panel based on the nCounter platform. This is a rare case of a patient who was treated with neoadjuvant alectinib and had paradoxical radiographic findings and pathological responses. The possibility that intratumoral immune heterogeneity was responsible for this phenomenon has been discussed. Based on the findings, it is argued that the pathological response should be an important basis for assessing the effectiveness of neoadjuvant alectinib therapy.<\/jats:p>","DOI":"10.3389\/fphar.2023.1140894","type":"journal-article","created":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T07:35:16Z","timestamp":1692344116000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Case Report: ALK rearranged locally advanced lung adenocarcinoma showing inconsistent radiographic findings and pathological responses during neoadjuvant alectinib therapy"],"prefix":"10.3389","volume":"14","author":[{"given":"Peijun","family":"Cao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingchun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruifeng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangsheng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zihe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongbing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minghui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sen","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.1158\/1078-0432.Ccr-15-3101","article-title":"EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: A retrospective analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin. cancer Res. official J. Am. Assoc. Cancer Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.2147\/ott.S334213","article-title":"Feasibility and safety of neoadjuvant alectinib in pulmonary invasive mucinous adenocarcinoma with ALK rearrangement: case report and literature review","volume":"14","author":"Gu","year":"2021","journal-title":"OncoTargets Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"622509","DOI":"10.3389\/fimmu.2020.622509","article-title":"Exhausted CD8+T cells in the tumor immune microenvironment: new pathways to therapy","volume":"11","author":"Jiang","year":"2020","journal-title":"Front. Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.cllc.2021.02.014","article-title":"Phase II, open-label, single-arm, multicenter study to assess the activity and safety of alectinib as neoadjuvant treatment in surgically resectable stage III ALK-positive NSCLC: ALNEO trial","volume":"22","author":"Leonetti","year":"2021","journal-title":"Clin. lung cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.lungcan.2018.09.010","article-title":"Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer","volume":"125","author":"Liu","year":"2018","journal-title":"Lung Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1016\/j.jtho.2019.07.017","article-title":"Rapid acquisition of alectinib resistance in ALK-positive lung cancer with high tumor mutation burden","volume":"14","author":"Makimoto","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","volume":"31","author":"Mok","year":"2020","journal-title":"Ann. Oncol. official J. Eur. Soc. Med. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1158\/1078-0432.Ccr-15-0016","article-title":"Induction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in non-small cell lung cancer","volume":"21","author":"Ota","year":"2015","journal-title":"Clin. cancer Res. official J. Am. Assoc. Cancer Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.lungcan.2015.03.022","article-title":"Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK-positive NSCLC: implications for disease assessment and management","volume":"88","author":"Ou","year":"2015","journal-title":"Lung Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.lungcan.2016.03.008","article-title":"Alectinib induced CNS radiation necrosis in an ALK+NSCLC patient with a remote (7 years) history of brain radiation","volume":"96","author":"Ou","year":"2016","journal-title":"Lung Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/intimm\/dxy042","article-title":"Immune suppression and reversal of the suppressive tumor microenvironment","volume":"30","author":"Shimizu","year":"2018","journal-title":"Int. Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40425-018-0355-5","article-title":"Immune oncology, immune responsiveness and the theory of everything","volume":"6","author":"Turan","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.21037\/tcr-21-642","article-title":"Perioperative alectinib in a patient with locally advanced anaplastic lymphoma kinase positive non-small cell lung cancer (NSCLC): A case report","volume":"10","author":"Yue","year":"2021","journal-title":"Transl. cancer Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.jtho.2018.10.161","article-title":"Neoadjuvant crizotinib in resectable locally advanced non-small cell lung cancer with ALK rearrangement","volume":"14","author":"Zhang","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1016\/j.jtho.2019.12.133","article-title":"Feasibility and safety of neoadjuvant alectinib in a patient with ALK-positive locally advanced NSCLC","volume":"15","author":"Zhang","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1007\/s00432-020-03360-1","article-title":"Pseudoprogression and hyperprogression in lung cancer: A comprehensive review of literature","volume":"146","author":"Zhou","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1140894\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T07:35:18Z","timestamp":1692344118000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1140894\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,17]]},"references-count":16,"alternative-id":["10.3389\/fphar.2023.1140894"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1140894","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,17]]},"article-number":"1140894"}}